Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study

Anuj Bhargava, Vicky Chan, Edward S Kimball, David S Oyer, Anuj Bhargava, Vicky Chan, Edward S Kimball, David S Oyer

Abstract

Background: This post-hoc sub-analysis investigated whether age (<65 years vs ≥65 years) affects glycemic control or hypoglycemic risk in patients with type 2 diabetes mellitus (T2DM) treated with once-daily insulin detemir.

Methods: This was a 26-week, randomized, open-label, phase IV trial involving 2812 patients at 1083 predominantly primary care sites throughout the United States, of which 541 were designated for investigator-led insulin titration. The main efficacy measure was change in HbA1c (A1C) from baseline to Week 26. Patients were stratified by age in the sites designated for the investigator-led titration of insulin detemir. Safety measures included adverse events and change in hypoglycemic event rates from baseline to Week 26.

Results: At Week 26, mean A1C and fasting plasma glucose decreased in both groups, but mean differences in change from baseline were not significant between groups. Within the group ≥65 years, significant reductions occurred for all daytime hypoglycemia, but there was no significant change from baseline in the other categories. In the group <65 years, reductions from baseline were significant for all hypoglycemic event categories. Changes in hypoglycemia rates from baseline were not significantly different between the age groups and there was no weight increase in either age group.

Conclusions: This analysis demonstrates that insulin detemir has similar efficacy and safety profiles for patients with T2DM ≥65 years compared with <65 years when treated via an investigator-led algorithm.

Figures

Fig. 1
Fig. 1
HbA1c (A1C) (mean ± SE) in patients aged <65 and ≥65 years
Fig. 2
Fig. 2
Fasting plasma glucose (FPG) (mean ± SE) in patients aged

References

    1. California Healthcare Foundation/American Geriatrics Society Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 suppl):S265–S280. doi: 10.1046/j.1532-5415.51.5s.1.x.
    1. Sinclair A, Morley JE. How to manage diabetes mellitus in older persons in the 21st century: applying these principles to long term diabetes care. J Am Med Dir Assoc. 2013;14(11):777–780. doi: 10.1016/j.jamda.2013.09.001.
    1. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009;7(6):324–342. doi: 10.1016/j.amjopharm.2009.12.002.
    1. Sue KM, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342–2356. doi: 10.1111/jgs.12035.
    1. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. Diabetes Care. 2012;35(12):2650–2664. doi: 10.2337/dc12-1801.
    1. Mallery LH, Ransom T, Steeves B, Cook B, Dunbar P, Moorhouse P. Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) Program. J Am Med Dir Assoc. 2013 [Epub ahead of print].
    1. Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13(6):497–502. doi: 10.1016/j.jamda.2012.04.012.
    1. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care. 2001;24(11):1936–1940. doi: 10.2337/diacare.24.11.1936.
    1. Centers for Medicare and Medicaid Services. MDS active resident information report: Third Quarter 2010. .
    1. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the US population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–294. doi: 10.2337/dc08-1296.
    1. Sloan FA, Bethel MA, Ruiz D, Jr, Shea AH, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med. 2008;168(2):192–199. doi: 10.1001/archinternmed.2007.35.
    1. Davis KL, Wei W, Meyers JL, Kilpatrick BS, Pandya N. Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Clin Interv Aging. 2014;9:1815–1822. doi: 10.2147/CIA.S65411.
    1. Munshi MN, Pandya N, Umpierrez GE, Digenio A, Zhou R, Riddle MC. Contributions of basal and prandial hyperglycemia to total hyperglycemia in older and younger adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61(4):535–541. doi: 10.1111/jgs.12167.
    1. Garber AJ, Clauson P, Pedersen CB, Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007;55(11):1735–1740. doi: 10.1111/j.1532-5415.2007.01414.x.
    1. Papa G, Fedele V, Chiavetta A, et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol. 2008;45(1):53–59. doi: 10.1007/s00592-007-0023-6.
    1. Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab. 2007;9(6):902–913. doi: 10.1111/j.1463-1326.2007.00804.x.
    1. Selam JL, Meneghini LF. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. Adv Ther. 2009;26(2):194–207. doi: 10.1007/s12325-009-0007-8.
    1. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56–64. doi: 10.1111/j.1463-1326.2004.00373.x.
    1. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269–1274. doi: 10.2337/dc05-1365.
    1. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. [Correction appears in Raslova K, et al. Diabetes Res Clin Pract. 2006;72:112] Diabetes Res Clin Pract. 2004;66(2):193–201. doi: 10.1016/j.diabres.2004.03.003.
    1. Oyer DS, Shepherd MD, Coulter FC, et al. A1c control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial) Am J Med. 2009;122(11):1043–1049. doi: 10.1016/j.amjmed.2008.12.026.
    1. Oyer DS, Shepherd MD, Coulter FC, et al. Efficacy and tolerability of self-titrated biphasic insulin aspart 70/30 in patients aged >65 years with type 2 diabetes: an exploratory post hoc subanalysis of the INITIATEplus trial. Clin Ther. 2011;33(7):874–883. doi: 10.1016/j.clinthera.2011.05.093.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327–336. doi: 10.4158/endp.19.2.a38267720403k242.
    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35(6):1364–1379. doi: 10.2337/dc12-0413.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit